Sarepta Therapeutics (SRPT) EBITDA Margin (2012 - 2026)
Sarepta Therapeutics' quarterly EBITDA Margin came in at 89.54% in Q1 2026, up 31483.0% year-on-year from N/an in Q1 2025, and up 196.36% quarter-over-quarter from 92.92% in Q4 2025.
Sarepta Therapeutics has reported EBITDA Margin for 13 years, with the latest figure at 89.54% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 31483.0% year-over-year to 89.54%; the trailing twelve-month figure through Mar 2026 stood at 1.94% (up 396.0% YoY), and the FY2025 full-year result was 31.83%, down 4330.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 89.54%, up from 92.92% in the prior quarter.
- The five-year high for EBITDA Margin was 89.54% in Q1 2026, with the low at 478.58% in Q1 2022.
- Average EBITDA Margin over 5 years is 76.0%, with a median of 44.99% recorded in 2025.
- Year-over-year, EBITDA Margin tumbled 36474 bps in 2022 and jumped 31483 bps in 2026.
- Tracing SRPT's EBITDA Margin over 5 years: stood at 63.66% in 2022, then soared by 116 bps to 10.19% in 2023, then soared by 141 bps to 24.56% in 2024, then plunged by 478 bps to 92.92% in 2025, then jumped by 196 bps to 89.54% in 2026.
- The last three EBITDA Margin figures came in at 89.54% (Q1 2026), 92.92% (Q4 2025), and 44.99% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | 89.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.54% |
| Dec 31, 2025 | -92.92% |
| Sep 30, 2025 | -44.99% |
| Jun 30, 2025 | 32.21% |
| Mar 31, 2025 | -225.29% |
| Dec 31, 2024 | 24.56% |
| Sep 30, 2024 | 7.90% |
| Jun 30, 2024 | 1.69% |
| Mar 31, 2024 | 8.35% |
| Dec 31, 2023 | 10.19% |
| Sep 30, 2023 | -12.21% |
| Jun 30, 2023 | -110.45% |
| Mar 31, 2023 | -203.36% |
| Dec 31, 2022 | -63.66% |
| Sep 30, 2022 | -124.39% |
| Jun 30, 2022 | -110.63% |
| Mar 31, 2022 | -478.58% |
| Dec 31, 2021 | -108.94% |
| Sep 30, 2021 | -25.43% |
| Jun 30, 2021 | -57.39% |
| Mar 31, 2021 | -113.83% |
| Dec 31, 2020 | -841.59% |
| Sep 30, 2020 | -873.58% |
| Jun 30, 2020 | -582.03% |
| Mar 31, 2020 | -127.91% |
| Dec 31, 2019 | -235.46% |
| Sep 30, 2019 | -127.56% |
| Jun 30, 2019 | -291.90% |
| Mar 31, 2019 | -87.95% |
| Dec 31, 2018 | -167.03% |
| Sep 30, 2018 | -96.86% |
| Jun 30, 2018 | -148.22% |
| Mar 31, 2018 | -55.15% |
| Dec 31, 2017 | -42.54% |
| Sep 30, 2017 | -103.82% |
| Jun 30, 2017 | -180.03% |
| Mar 31, 2017 | 514.96% |
| Dec 31, 2014 | -164,651.85% |
| Sep 30, 2014 | -2,761.76% |
| Jun 30, 2014 | -1,310.49% |
| Mar 31, 2014 | -465.37% |
| Dec 31, 2013 | -335.87% |
| Sep 30, 2013 | -1,008.40% |
| Jun 30, 2013 | -645.58% |
| Mar 31, 2013 | -940.63% |
| Dec 31, 2012 | -846.06% |
| Sep 30, 2012 | -654.26% |
| Jun 30, 2012 | 71.72% |
| Mar 31, 2012 | -157.90% |